Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Fludara (fludarabine)
• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer | Phase 1 | Status: COMPLETED